id	domain	url
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	orcid.org	https://orcid.org/0000-0001-5027-9992
dhrp-67	orcid.org	https://orcid.org/0000-0003-4146-3282
dhrp-67	orcid.org	https://orcid.org/0000-0001-5027-9992
dhrp-67	orcid.org	https://orcid.org/0000-0003-4146-3282
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	www.who.int	https://www.who.int/news/item/26-11-2021classification-of-omicron-(b.1.1.529)-sarscov-2-variant-of-concern
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19update-fda-authorizes-first-oral-antiviraltreatment-covid-19
dhrp-67	emergency.cdc.gov	https://emergency.cdc.gov/han/2022/han004
dhrp-67	www.who.int	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
dhrp-67	www.who.int	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
dhrp-67	www.who.int	https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
dhrp-67	www.nejm.org	https://www.nejm.org/doi/full/10.1056/nejmoa2118542
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
dhrp-67	emergency.cdc.gov	https://emergency.cdc.gov/han/2022/han00467.asp
dhrp-67	emergency.cdc.gov	https://emergency.cdc.gov/han/2022/han00467.asp
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	doi.org	https://doi.org/10.1101/2022.06.21.222
dhrp-67	www.dailymail.co.uk	https://www.dailymail.co.uk/news/article11065467/covid-reinfection-rate-treatmentbiden-taking-40-not-2-marketed.html
dhrp-67	www.forbes.com	https://www.forbes.com/sites/brucelee/2022
dhrp-67	www.cnn.com	https://www.cnn.com/2022/07/31/politics/jo
dhrp-67	health.ucsd.edu	https://health.ucsd.edu/news/releases/pages
dhrp-67	doi.org	https://doi.org/10.1101/2022.06.21.22276724
dhrp-67	doi.org	https://doi.org/10.1101/2022.06.21.22276724
dhrp-67	www.dailymail.co.uk	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html
dhrp-67	www.dailymail.co.uk	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html
dhrp-67	www.dailymail.co.uk	https://www.dailymail.co.uk/news/article-11065467/covid-reinfection-rate-treatment-biden-taking-40-not-2-marketed.html
dhrp-67	www.forbes.com	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6
dhrp-67	www.forbes.com	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6
dhrp-67	www.forbes.com	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6
dhrp-67	www.forbes.com	https://www.forbes.com/sites/brucelee/2022/06/30/dr-fauci-takes-2nd-course-of-paxlovid-after-suffering-covid-19-rebound/?sh=4964bf0315d6
dhrp-67	www.cnn.com	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html
dhrp-67	www.cnn.com	https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html
dhrp-67	health.ucsd.edu	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx
dhrp-67	health.ucsd.edu	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx
dhrp-67	health.ucsd.edu	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx
dhrp-67	health.ucsd.edu	https://health.ucsd.edu/news/releases/pages/2022-06-21-covid-19-rebound-after-taking-paxlovid-likely-due-to-insufficient-drug-exposure.aspx
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	covid.cdc.gov	https://covid.cdc.gov/covid-data-tracker/#variant-proportions
dhrp-67	covid.cdc.gov	https://covid.cdc.gov/covid-data-tracker/#variant-proportions
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	www.fda.gov	https://www.fda.gov/media/156152/download
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/pressannouncements/fda-takes-actions-expand-usetreatment-outpatients-mild-moderate-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-updatefda-authorizes-drug-combination-treatmentcovid-19
dhrp-67	www.paxlovid.com	https://www.paxlovid.com/?source=bing&hb
dhrp-67	www.nejm.org	https://www.nejm.org/doi/full/10.1056/nejm
dhrp-67	www.evusheld.com	https://www.evusheld.com/en/patient
dhrp-67	www.fda.gov	https://www.fda.gov/drugs/drug-safety-andavailability/fda-authorizes-revisionsevusheld-dosing
dhrp-67	www.fda.gov	https://www.fda.gov/media/156152/download
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
dhrp-67	www.fda.gov	https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19
dhrp-67	www.paxlovid.com	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds
dhrp-67	www.paxlovid.com	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds
dhrp-67	www.paxlovid.com	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds
dhrp-67	www.paxlovid.com	https://www.paxlovid.com/?source=bing&hbx_pk=s_paxlovid&skwid=43700068281647229&gclid=c926586053d315737f663a86b3210308&gclsrc=3p.ds
dhrp-67	www.nejm.org	https://www.nejm.org/doi/full/10.1056/nejmoa2116044
dhrp-67	www.nejm.org	https://www.nejm.org/doi/full/10.1056/nejmoa2116044
dhrp-67	www.evusheld.com	https://www.evusheld.com/en/patient
dhrp-67	www.fda.gov	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing
dhrp-67	www.fda.gov	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing
dhrp-67	www.fda.gov	https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org
dhrp-67	doi.org	https://doi.org/10.47488/dhrp.v2is3.67
dhrp-67	dhrproceedings.org	http://dhrproceedings.org